Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.54 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.51 |
| ▸ | CCR8 | P51685 | 4/20 | 0.50 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.48 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6496325 | 0.89 | KDM4E (0.58) | CYP3A4CYP2D6OPRM1OPRL1CCR8 | |
| SCHEMBL6499178 | 0.87 | CACNA1G (0.61) | CYP3A4CYP2D6OPRM1OPRL1CCR8 | |
| SCHEMBL6505921 | 0.85 | C5AR1 (0.57) | CYP3A4CYP2D6OPRM1OPRL1CCR8 | |
| SCHEMBL7066869 | 0.83 | OPRM1 (0.51) | CYP3A4CYP2D6OPRM1OPRL1CCR8 | |
| SCHEMBL6496417 | 0.83 | KDM4E (0.61) | CYP3A4CYP2D6OPRM1OPRL1CCR8 | |
| SCHEMBL6508675 | 0.83 | CYP3A4 (0.52) | CYP3A4CYP2D6OPRM1OPRL1CCR8 | |
| SCHEMBL6495959 | 0.82 | CYP3A4 (0.53) | CYP3A4CYP2D6OPRM1OPRL1CCR8 | |
| SCHEMBL7066463 | 0.81 | CYP3A4 (0.62) | CYP3A4CYP2D6OPRM1OPRL1CCR8 | |
| SCHEMBL6507890 | 0.79 | CYP3A4 (0.49) | CYP3A4CYP2D6OPRM1OPRL1C5AR1 | |
| SCHEMBL7070692 | 0.79 | OPRM1 (0.57) | CYP3A4CYP2D6OPRM1OPRL1CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | CCR8, CCL11, CCR5 | CYP3A4 1514/4885CYP2D6 1424/4885OPRM1 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.